Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Taskforce To Study Resistance Emergence and Antimicrobial Development Technology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.00866-17. Print 2017 Oct.
As a growing number of clinical isolates of are resistant to most antibiotics, new treatment options that are effective against these drug-resistant strains are desperately needed. The majority of the linkages in the cell wall peptidoglycan of are synthesized by nonclassical transpeptidases, namely, the l,d-transpeptidases. Emerging evidence suggests that these enzymes represent a new molecular vulnerability in this pathogen. Recent studies have demonstrated that inhibition of these enzymes by the carbapenem class of β-lactams determines their activity against Here, we studied the interactions of β-lactams with two l,d-transpeptidases in , namely, Ldt and Ldt, and found that both the carbapenem and cephalosporin, but not penicillin, subclasses of β-lactams inhibit these enzymes. Contrary to the commonly held belief that combination therapy with β-lactams is redundant, doripenem and cefdinir exhibit synergy against both pansusceptible and clinical isolates that are resistant to most antibiotics, which suggests that dual-β-lactam therapy has potential for the treatment of Finally, we solved the first crystal structure of an l,d-transpeptidase, Ldt, and using substitutions of critical amino acids in the catalytic site and computational simulations, we describe the key molecular interactions between this enzyme and β-lactams, which provide an insight into the molecular basis for the relative efficacy of different β-lactams against .
由于越来越多的临床分离株对大多数抗生素具有耐药性,因此迫切需要新的治疗方法来对抗这些耐药菌株。 大多数 细胞壁肽聚糖的连接是由非经典转肽酶(即 l,d-转肽酶)合成的。 新出现的证据表明,这些酶代表该病原体的新的分子弱点。 最近的研究表明,碳青霉烯类β-内酰胺类抗生素通过抑制这些酶来发挥其对 的活性。 在这里,我们研究了β-内酰胺类抗生素与 中的两种 l,d-转肽酶(即 Ldt 和 Ldt)的相互作用,发现碳青霉烯类和头孢菌素类而非青霉素类β-内酰胺类抗生素均能抑制这些酶。 与普遍认为的β-内酰胺类联合治疗是多余的观点相反,多利培南和头孢地尼对泛敏感 株和对大多数抗生素耐药的临床分离株均表现出协同作用,这表明双重β-内酰胺疗法具有治疗 的潜力。 最后,我们解决了第一个 l,d-转肽酶(Ldt)的晶体结构,并通过在催化位点替换关键氨基酸和计算模拟,描述了该酶与β-内酰胺类抗生素之间的关键分子相互作用,这为不同β-内酰胺类抗生素对 的相对疗效提供了分子基础的深入了解。